Navigation Links
JAK2 Inhibitor Shows Potent Activity in Cells From MPD Patients
Date:1/30/2008

danani of the Mayo clinic said: "In ex vivo studies, we have seen encouraging preliminary results with Cytopia's compounds including the inhibition of erythroid colony growth from PV patients harboring the JAK2 V617F mutation."

Cytopia's Research Director Dr Chris Burns stated: "This data is important validation that our selective JAK2 inhibitors stop the proliferation of mutant cells from patients with these diseases at clinically achievable doses."

Cytopia is developing JAK2 inhibitors for the treatment of MPDs and other solid and blood cancers. In addition, other inhibitors of JAK2 are under development for cardiovascular and ophthalmic diseases.

About Cytopia

Cytopia Ltd is an Australian headquartered biotechnology company focused on the discovery and development of new drugs to treat cancer. Cytopia conducts its research and development via subsidiaries based in Melbourne, Australia and New York and specializes in discovering new molecules that can inhibit enzymes known as kinases, an exciting new class of drugs.

http://www.cytopia.com.au

Relevant Links:

http://www.mpdfoundation.org

http://www.mpd-oz.org


'/>"/>
SOURCE Cytopia Limited
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2

Related medicine technology :

1. Nuvelo Initiates Phase 1 Clinical Trial of Thrombin Inhibitor, NU172
2. Kosan Initiates Phase 2 Trial of Alvespimycin, Second-Generation Hsp90 Inhibitor, in HER2-Positive Metastatic Breast Cancer
3. SuperGen Reports Initiation of Multi-arm Phase 1b Trial of Novel Tyrosine Kinase Inhibitor
4. PTC Therapeutics Presents Encouraging Phase 1 Results of its Novel VEGF Inhibitor, PTC299, at 30th Annual San Antonio Breast Cancer Symposium
5. Exelixis Presents Encouraging Phase 1 Data For XL019, A Novel Selective Inhibitor of JAK2
6. Kosan Presents Updated Data on Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma at Ash
7. TargeGen Announces Planned Initiation of Clinical Trial of JAK2 Inhibitor TG101348 in Myeloproliferative Disease Patients, and Presentations at ASH
8. VioQuest Pharmaceuticals Announces Dosing of First Patient in Phase IIa Solid Tumor Study for Lenocta(TM), a Novel Protein Tyrosine Phosphatase Inhibitor
9. BiPar Begins Phase 2 Study of Lead PARP Inhibitor in Triple-Negative Breast Cancer Based on Overexpression Biomarker Data
10. Roches Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks
11. Potent Hepatitis C Virus Inhibitors Show Efficacy and Potential for Once Daily Dosing in Preclinical Studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/7/2008)...Call/ -- Ardea Biosciences, Inc.,(Nasdaq: RDEA ) ... Potent,and Highly Selective MEK1/2 Inhibitor is B...ed Chronic Colitis in Mice," was presented at the,...nual Meeting in Orlando,Florida. The poster, whic...9, the Company,s lead mitogen-activated ERK kinase...
(Date:10/6/2008)...ber 7 /-,Sosei Group Corpor...ra,Group plc ("Vectura"; LSE: VEC), announce resul..., safety and tolerability of NVA237 presented at t...iety (ERS) in Berlin,Germany. The new data show t...ed long-acting muscarinic antagonist (LAMA), provi...
(Date:10/6/2008)...the understanding of and possible treatme...LERICA, Mass., Oct. 6 /- Seahorse Bio...ver analytical instrument for the,kinetic measurem...asmic,glycolysis in cells in a 96 well microplate....r bioenergetics have been relatively unchanged sin...
(Date:10/6/2008)... The American College of Nutrition ...- New research on the benefits of,pro...he American College of,Nutrition (ACN) Annual Meet...biotics in Health and Disease." Scientific experts... discussed the potential uses for,probiotics in ch...
Breaking Medicine Technology:Ardea Biosciences Presents Preclinical Anti-Inflammatory Data on its Lead MEK Inhibitor, RDEA119, at the ACG 2008 Annual Meeting 2Ardea Biosciences Presents Preclinical Anti-Inflammatory Data on its Lead MEK Inhibitor, RDEA119, at the ACG 2008 Annual Meeting 3Ardea Biosciences Presents Preclinical Anti-Inflammatory Data on its Lead MEK Inhibitor, RDEA119, at the ACG 2008 Annual Meeting 4NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium 2NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium 3NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium 4NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium 5Seahorse Bioscience Announces the XF96 Extracellular Flux Analyzer for Cellular Bioenergetics 2Seahorse Bioscience Announces the XF96 Extracellular Flux Analyzer for Cellular Bioenergetics 3'Friendly' Bacteria Can Benefit Health Throughout the Lifecycle 2'Friendly' Bacteria Can Benefit Health Throughout the Lifecycle 3'Friendly' Bacteria Can Benefit Health Throughout the Lifecycle 4SEIU Launches Multi State Grassroots Campaign Calling on the Carlyle Group to Put Care Above Profits in Buyout of Nations Largest Nursing Home Chain 2784 1SEIU Launches Multi State Grassroots Campaign Calling on the Carlyle Group to Put Care Above Profits in Buyout of Nations Largest Nursing Home Chain 2784 2MacroChem Acquires Rights to Pexiganan a Novel Topical Anti Infective for Treatment of Diabetic Foot Infections From Genaera 439 1MacroChem Acquires Rights to Pexiganan a Novel Topical Anti Infective for Treatment of Diabetic Foot Infections From Genaera 439 2MacroChem Acquires Rights to Pexiganan a Novel Topical Anti Infective for Treatment of Diabetic Foot Infections From Genaera 439 3MacroChem Acquires Rights to Pexiganan a Novel Topical Anti Infective for Treatment of Diabetic Foot Infections From Genaera 439 4MacroChem Acquires Rights to Pexiganan a Novel Topical Anti Infective for Treatment of Diabetic Foot Infections From Genaera 439 5MacroChem Acquires Rights to Pexiganan a Novel Topical Anti Infective for Treatment of Diabetic Foot Infections From Genaera 439 6Combination vaccines okay for infants study shows 2777 1Combination vaccines okay for infants study shows 2777 2Combination vaccines okay for infants study shows 2777 3Unilens Names Eschenbach Optik Exclusive Worldwide Distributor of the UniVision 28R 29 Low Vision Lens 2772 1Unilens Names Eschenbach Optik Exclusive Worldwide Distributor of the UniVision 28R 29 Low Vision Lens 2772 2Unilens Names Eschenbach Optik Exclusive Worldwide Distributor of the UniVision 28R 29 Low Vision Lens 2772 3
...WIRE)--May 10, 2007 - According to,The Waismann Me...emale respondents seeking treatment for opiate dep...h as Vicodin, OxyContin, Percocet,and Fentanyl wer...f,the mothers who reported a dependency said they ...ann, registered addiction,specialist for the Waism...
... Developing Therapies to Prevent,and Reverse Ather...10, 2007 /PRNewswire/ -- KineMed, Inc.,a pathway-...unced,today the first method for measuring the eff... the pathway known as reverse cholesterol,transpor...excess,cholesterol can be removed from tissues and...
Other Medicine Technology:Waismann Method Survey Reveals 65 Percent of Women Seeking Opiate,Dependency Treatment Are Mothers 2KineMed Presents Data Measuring Changes in Reverse Cholesterol,Transport for the First Time 2KineMed Presents Data Measuring Changes in Reverse Cholesterol,Transport for the First Time 3
(Date:10/7/2008)...RNewswire-FirstCall/ -- Stallergenes S.A.,today an...greement with,Catalent for the promotion and distr...FLEX(R), co-developed and co-manufactured by Catal...sts of a syringe pre-filled with adrenaline, which....3 and 0.15 mg), in an,autoinjector device. The Me...
(Date:10/7/2008)...of asthma in a young child may well be more challe..., according to a review of research and clinical e... Indiana University School of Medicine and Riley H... issue of Clinical Pediatrics . , "Wheezing ca... Professor of Pediatrics at the IU School of Medic...
(Date:10/7/2008)...rial Specialties, Mfg. is pleased to announce the ...hese filters are exclusively available from Indust... push-to-connect style fittings integrated into th...ne filter offers versatility and customization for... (PRWEB) October 7, 2008 -- Exclusively availa...
(Date:10/6/2008)...fight against childhood obesity, researcher notes ... Three-quarters of middle schools have vending mac...new study finds. , The research demonstrates th...ls, and "that those vending machines don,t always ...y Virus, a registered dietitian with the Center fo...
Breaking Medicine News(10 mins):Health News:Stallergenes Partners With Catalent and the Medical House for Commercialization of Adrenaline Autoinjector in Europe 2Health News:Wheezing and asthma in young children 2Health News:Vending Machines Found in Most Middle Schools 2
...i Co. Ltd, charity organizations, The Alzheimer's ...e Concern will appeal have lodged// an appeal on F...trict access to Alzheimer's drugs. The National I...lence (NICE) declared earlier that the drugs were ...
...ad announced yesterday a campaign to reduce the nu...ne of the commonest causes of death// among those ...t year 1,300 young men killed themselves. The gove...ave definitely fallen, but it is still much higher...
...ealed that almost one in five youngsters have admi... study the effects of these pills on driving//. L... of New Zealand, Imogen Thompson said that partici...essed for the influence of party pills, with and w...
... recent findings it is said that a new disease is ...in’s food watchdog has requested// people to avoid...ds Agency advices caution people about the disease... and classic scrapie, a brain-wasting disease seen...
Other Medicine News:Health News:Appeals Against The New Resolution By NICE Increases 2Health News:UK Government Plans A Campaign To Help Reduce Suicide Rates Among Men 2
The IDENTI-PRINT II ID system functions as a complete, hospital wide patient identification system. It integrates the benefits of bedside labeling into a multipurpose ID band that consolidates admitt
Volks drive to provide the best optics enables us to bring you a lens with the highest resolution available in a non-contact slit lamp lens. The astonishing detail allows true 3D viewing of the retin
...nting solution that can encode smart labels at the...of the most versatile in the industry! Designed fo...ands and smart labels, the R2844-Z meets the needs...d and more connectivity choices-such as standard s...
The Health Trax System includes real time location services (RTLS), long range active RFID, telemetery and choke-point visibility all in a single intergrated infrastructure. Health Trax Standards-bas
Medicine Products: